Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium

View Full Paper
Ask AI
Bookmark
Share

Authors

DNDeedra NicoletNANajla Al AliAAAlexander J. Ambinder

Discussion

Loading...

Member takes

Overview

Observational analysis showed comparable overall survival in older AML patients treated with venetoclax or intensive chemotherapy, indicating important treatment implications.

Key Points

  • Median overall survival was similar for acute myeloid leukemia patients aged over 60 treated with venetoclax and intense chemotherapy.
  • Key mutations DNMT3A and RUNX1 were prevalent in the study cohort of AML patients.
  • Analysis of treatment response and outcomes used data from the MARROW consortium with rigorous methodologies.
  • Findings support using venetoclax for older patients with aggressive disease types to minimize chemotherapy toxicity.

Cite This Study

Nicolet et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d891https://doi.org/10.1182/blood-2025-5157
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)2025
  2. 2Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)2025
  3. 3Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  4. 4Assessment of racial and age disparities in response and survival among acute myeloid leukemia (AML) patients treated with hypomethylating agents (HMA) and venetoclax.2026
  5. 5Treatment-specific prognostic performance of ELN 2022, ELN 2024, and beat AML 2024: A real-world AML validation study2025